Alpha Cognition Inc. (OTC:ACOGF – Get Rating) – Stock analysts at Zacks Small Cap lifted their FY2023 earnings estimates for Alpha Cognition in a research report issued on Wednesday, March 15th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($0.09) per share for the year, up from their prior estimate of ($0.17). The consensus estimate for Alpha Cognition's current full-year earnings is ($0.17) per share.

Separately, Raymond James cut shares of Alpha Cognition from an "outperform" rating to a "market perform" rating in a report on Friday, February 10th.

Alpha Cognition Price Performance

Shares of Alpha Cognition stock opened at C$0.30 on Friday. The firm has a market cap of C$18.30 million, a price-to-earnings ratio of -1.67 and a beta of 2.92. The stock has a 50-day simple moving average of C$0.27 and a 200-day simple moving average of C$0.30. Alpha Cognition has a 52-week low of C$0.15 and a 52-week high of C$1.08.

About Alpha Cognition

(Get Rating)

Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.

Featured Stories

• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows
• Europe Raises Interest Rates, Should the Fed Follow?

Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.